Human study PLS-00245

Study of Healthy Aging and Physical Function With Elamipretide

Other design · Not reported participants enrolled

Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

Study of Healthy Aging and Physical Function With Elamipretideregistry entry · NCT07275424 (RECRUITING, no results posted, planned enrollment 30)

Design and participants

Design: Other design
Population: Healthy aging adults (registered condition: Aging, Healthy); eligibility details not provided in the record
Conditions: Aging, Healthy
Planned enrollment (registry): 30
Enrolled: Not reported
Randomized: Not reported
Completed follow-up: Not reported

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

Elamipretide (intervention) · elamipretide · Elamipretide solution supplied in multi-dose glass vials with phosphate buffer and benzyl alcohol; regimen not stated in the record · Not reported assigned

What the authors reported

As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

Adverse events

None reported. That is not evidence of safety, and how safety was monitored isn’t described.

Peptide Library’s assessment

An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

Limitations

other: The study is still recruiting and the registry shows no results, so no outcome data are available to appraise.
no control group: Only an elamipretide intervention is listed in the registry. No placebo or comparator arm and no randomization are described.
small or imprecise: Estimated enrollment is only 30 participants, which limits the precision of any future estimates.
inappropriate population: Participants are healthy aging individuals, not people with Barth syndrome or primary mitochondrial myopathy.
selective reporting: The stored registry record lists no registered outcomes, so prespecified endpoints cannot be checked against future reports.

No risk-of-bias assessment has been published for this study’s results.

Claims this study informs

Improves function in Barth syndrome: not eligible (wrong population) for “Muscle strength, exercise capacity and fatigue”
Improves exercise capacity in primary mitochondrial myopathy: not eligible (wrong population) for “Six-minute walk distance and fatigue”
Is safe for human administration: not eligible (insufficient data) for “Adverse events, including injection-site reactions, and discontinuations”

Where each value comes from

arms: NCT NCT07275424, registry (interventions field) · extracted by AI (automated, not verified by a person)
design: NCT NCT07275424, registry (study_type, phases and interventions fields) · extracted by AI (automated, not verified by a person)
limitations: NCT NCT07275424, registry (status and has_results fields) · extracted by AI (automated, not verified by a person)
participants: NCT NCT07275424, registry (enrollment and enrollment_type fields) · extracted by AI (automated, not verified by a person)
population: NCT NCT07275424, registry (conditions field) · extracted by AI (automated, not verified by a person)

Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).